Mona Bafadhel

12.5k total citations · 8 hit papers
160 papers, 5.1k citations indexed

About

Mona Bafadhel is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Emergency Medical Services. According to data from OpenAlex, Mona Bafadhel has authored 160 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 133 papers in Pulmonary and Respiratory Medicine, 81 papers in Physiology and 32 papers in Emergency Medical Services. Recurrent topics in Mona Bafadhel's work include Chronic Obstructive Pulmonary Disease (COPD) Research (122 papers), Asthma and respiratory diseases (79 papers) and Respiratory Support and Mechanisms (47 papers). Mona Bafadhel is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (122 papers), Asthma and respiratory diseases (79 papers) and Respiratory Support and Mechanisms (47 papers). Mona Bafadhel collaborates with scholars based in United Kingdom, United States and Germany. Mona Bafadhel's co-authors include Christopher E. Brightling, Ian Pavord, Stephanie A. Christenson, Benjamin M. Smith, Nirupama Putcha, Michael R. Barer, Vijay Mistry, Sebastian L. Johnston, Malin Fagerås and Koirobi Haldar and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Mona Bafadhel

144 papers receiving 5.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chronic obstructive pulmonary disease

2022 639 citations Stephanie A. Christenson, Mona Bafadhel et al. profile →
Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease: A Randomized Placebo-Controlled Trial

2012 422 citations Mona Bafadhel, Mitesh Pancholi et al. American Journal of Respiratory and Critical Care Medicine profile →
Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials

2018 302 citations Mona Bafadhel et al. The Lancet Respiratory Medicine profile →
Lung microbiome dynamics in COPD exacerbations

2016 280 citations Mona Bafadhel, Christopher E. Brightling et al. European Respiratory Journal profile →
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation

2024 102 citations Surya P. Bhatt, Klaus F. Rabe et al. profile →
Development and validation of a new algorithm for improved cardiovascular risk prediction

2024 52 citations Mona Bafadhel, Richard Russell et al. profile →
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype

2025 22 citations Frank C. Sciurba, Gerard J. Criner et al. profile →
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials

2025 18 citations Surya P. Bhatt, Klaus F. Rabe et al. The Lancet Respiratory Medicine profile →

Peers

Countries citing papers authored by Mona Bafadhel

Since Specialization

Citations

This map shows the geographic impact of Mona Bafadhel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mona Bafadhel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mona Bafadhel more than expected).

Fields of papers citing papers by Mona Bafadhel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mona Bafadhel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mona Bafadhel. The network helps show where Mona Bafadhel may publish in the future.

Co-authorship network of co-authors of Mona Bafadhel

This figure shows the co-authorship network connecting the top 25 collaborators of Mona Bafadhel. A scholar is included among the top collaborators of Mona Bafadhel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mona Bafadhel. Mona Bafadhel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial 2025 ·The Lancet Respiratory Medicine ·Stephanie A. Christenson, Nicola A. Hanania, Surya P. Bhatt, Mona Bafadhel, Klaus F. Rabe, Claus Vogelmeier, Alberto Papi, (unknown), Elizabeth Laws, Paula Dakin, Ashish Bansal, Xin Lu, (unknown), Jennifer Maloney, Lacey B. Robinson, Raolat M. Abdulai	5
2	Dupilumab Improves Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS 2025 ·CHEST Journal ·Surya P. Bhatt, Klaus F. Rabe, Nicola A. Hanania, Claus Vogelmeier, Mona Bafadhel, (unknown), Alberto Papi, Dave Singh, Elizabeth Laws, Paula Dakin, Jennifer Maloney, Xin Lu, (unknown), Ashish Bansal, Raolat M. Abdulai, Lacey B. Robinson	1
3	Pharmacodynamic Effects of Benralizumab on Eosinophil-related Biomarkers in COPD: A Biomarker Analysis of the GALATHEA Study 2025 ·American Journal of Respiratory and Critical Care Medicine ·Christopher McCrae, Gerard J. Criner, Christopher E. Brightling, Mona Bafadhel, (unknown), Maria Jison	1
4	Treating Eosinophilic Exacerbations of Airways Disease With Benralizumab Reduces Cumulative Systemic Corticosteroid Exposure at 90 Days 2025 ·American Journal of Respiratory and Critical Care Medicine ·Sanjay Ramakrishnan, Richard Russell, Mona Bafadhel	0
5	Effect of budesonide/glycopyrronium/formoterol fumarate dihydrate on cardiopulmonary outcomes in COPD: rationale and design of the THARROS trial 2025 ·ERJ Open Research ·Fernando J. Martinez, John R. Hurst, MeiLan K. Han, David Price, Jinping Zheng, David D. Berg, (unknown), Mona Bafadhel, Carolyn S.P. Lam, Martin Fredriksson, Martín Cowie, (unknown), Karin Bowen, (unknown), Mehul Patel	0
6	IN PATIENTS WITH MODERATE OR SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION, DUPILUMAB DOES NOT IMPACT BLOOD EOSINOPHIL LEVELS: PHASE 3 BOREAS TRIAL 2024 ·CHEST Journal ·Mona Bafadhel, Stephanie A. Christenson, (unknown), (unknown), Claus Vogelmeier, (unknown), Dave Singh, (unknown), Paula Dakin, Ashish Bansal, Xin Lü, (unknown), (unknown), Lacey B. Robinson, (unknown)	1
7	Dupilumab Improves Pre-bronchodilator Lung Function Measures in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation: Data From the Phase 3 Boreas Trial 2024 ·Alberto Papi, Nicola A. Hanania, Surya P. Bhatt, Klaus F. Rabe, Claus Vogelmeier, Mona Bafadhel, Stephanie A. Christenson, Dave Singh, Elizabeth Laws, (unknown), Ashish Bansal, (unknown), Dirk Bauer, Jennifer Maloney, Lacey B. Robinson, Raolat M. Abdulai	1
8	Efficacy of Mepolizumab in Patients With Chronic Obstructive Pulmonary Disease With or Without Chronic Bronchitis: Post Hoc Analysis of the METREX and METREO Phase 3 Trials 2024 ·Frank C. Sciurba, (unknown), Stephanie Korn, Mona Bafadhel, (unknown), (unknown), Àlvar Agustí, Bhabita Mayer	0
9	Tezepelumab in Adults With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD): Efficacy and Safety From the Phase 2a COURSE Study 2024 ·(unknown), Mona Bafadhel, Christopher E. Brightling, Klaus F. Rabe, MeiLan K. Han, Mohit Bhutani, Jean Bourbeau, S. Christenson, Mark T. Dransfield, Parameswaran Nair, (unknown), (unknown), Gun Almqvist, (unknown), (unknown), Néstor A. Molfino, Sandhia Ponnarambil	0
10	In the Phase 3 Boreas Trial, Baseline Blood Eosinophils and Baseline Fractional Exhaled Nitric Oxide Levels Predict the Response to Dupilumab in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease and Type 2 Inflammation 2024 ·Stephanie A. Christenson, Nicola A. Hanania, Surya P. Bhatt, Mona Bafadhel, Klaus F. Rabe, Claus Vogelmeier, Alberto Papi, Dave Singh, Elizabeth Laws, (unknown), Ashish Bansal, Xun‐Xi Lu, Dirk Bauer, Jennifer Maloney, (unknown), Raolat M. Abdulai	1
11	QRISK3 underestimates the risk of cardiovascular events in patients with COPD 2023 ·Thorax ·(unknown), Zhiwei Gao, Jennifer K Quint, Richard Russell, John R. Hurst, (unknown), Don D. Sin, Wenjia Chen, Mona Bafadhel, Mohsen Sadatsafavi	13
12	A Long-Term Study of Adverse Outcomes Associated With Oral Corticosteroid Use in COPD 2023 ·International Journal of COPD ·Gary Tse, Benjamin Emmanuel, Cono Ariti, Mona Bafadhel, Alberto Papi, Victoria Carter, Jiandong Zhou, Derek Skinner, Xiao Xu, Hana Müllerová, David Price	12
13	Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis 2023 ·International Journal of COPD ·Dave Singh, Gerard J. Criner, Àlvar Agustí, Mona Bafadhel, (unknown), Gabriela Luporini Saraiva, Yue Song, Idlir Licaj, Maria Jison, Ubaldo J. Martin, Ioannis Psallidas	17
14	Recovery of Breakthrough Asthma Attacks Treated With Oral Steroids While on Monoclonal Antibody Therapy: Protocol for a Prospective Observational Study (BOOST) 2023 ·JMIR Research Protocols ·Imran Howell, Mahdi Mahdi, Mona Bafadhel, Timothy Hinks, Sanjay Ramakrishnan, J. Mark Melhorn, Maisha Jabeen, Ian Pavord	5
15	Predictive modeling of COPD exacerbation rates using baseline risk factors 2022 ·Therapeutic Advances in Respiratory Disease ·Dave Singh, John R. Hurst, Fernando J. Martínez, Klaus F. Rabe, Mona Bafadhel, Martin Jenkins, (unknown), Paul Dorinsky, Patrick Darken	14
16	Performance of cough monitoring by Albus Home, a contactless and automated system for nocturnal respiratory monitoring at home 2022 ·ERJ Open Research ·(unknown), Richard Russell, (unknown), (unknown), (unknown), George B. Cunningham, (unknown), Maarten De Vos, Imran Satia, Mona Bafadhel, Ian Pavord	8
17	Performance of Contactless Respiratory Rate Monitoring by Albus HomeTM, an Automated System for Nocturnal Monitoring at Home: A Validation Study 2022 ·Sensors ·(unknown), Richard Russell, (unknown), (unknown), Maarten De Vos, Ian Pavord, Mona Bafadhel	4
18	Infection, inflammation and intervention: mechanistic modelling of epithelial cells in COVID-19 2021 ·Journal of The Royal Society Interface ·Nabil T. Fadai, (unknown), Helen M. Byrne, Philip K. Maini, Mona Bafadhel, Dan V. Nicolau	18
19	The Blood Eosinophil Trajectory Of Patients With COPD Through Stable State, Exacerbation And Recovery 2016 ·American Journal of Respiratory and Critical Care Medicine ·(unknown), Christopher E. Brightling, Ian Pavord, Richard Russell, Mona Bafadhel	1
20	Associations between quantitative CT measures and airway inflammation in COPD 2013 ·European Respiratory Journal ·Bethan Barker, Ruth Hartley, (unknown), M. Shelley, (unknown), Mitesh Pancholi, Nisha Rana, Mini Pakkal, Sumit Gupta, Mona Bafadhel, Christopher E. Brightling	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact